News

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Kai Beckmann, CEO of Electronics at Merck KGaA, discusses Europe's competitiveness in AI development. Gavin Newsom's warning to Donald Trump over plan for Texas Republicans 'Gilligan's Island': Untold ...
Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...
Merck, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by ...
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...